Ping An Insurance (Group) Company of China, Ltd., established in 1988 in Shenzhen, is a leading personal integrated financial services provider in China. As the first insurance company in the country to adopt a shareholding structure, Ping An has evolved to encompass three core businesses: insurance, banking, and investment. The company aims to foster the parallel growth of its traditional and non-traditional financial ventures. In its traditional business, Ping An focuses on creating a financial supermarket and enhancing customer migration. Concurrently, it seeks to innovate within non-traditional sectors by seamlessly integrating financial services into everyday life, covering areas such as health, housing, and entertainment. The Group strives to establish an integrated financial services platform that offers a comprehensive customer experience, promotes sustainable profit growth, and ensures long-term stability for its shareholders.
No.1333, Lujiazui Ring Road, Pudong New District, Shanghai, 200120, China
Dong Liu
Principal Partner
Mingzhe Ma
Chairman and CEO
Hui Zhou
Partner
Past deals in Cayman Islands
Xgene Pharmaceutical
Series C in 2021
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.
Xgene Pharmaceutical
Series B in 2018
Xgene Pharmaceutical Inc. is a late-clinical stage pharmaceutical company established in 2015, based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors. Utilizing proprietary linker technology, Xgene creates novel, multimodal conjugated molecules that enhance the efficacy and tolerability of pain medications. The company's current programs are dedicated to addressing unmet needs in neurological disorders, making significant strides in the development of innovative treatments for these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.